Contineum Therapeutics, Inc. Class A Common Stock
CTNM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $50,000 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Cost of Goods Sold | $258 | $0 | $329 | $0 |
| Gross Profit | -$258 | $50,000 | -$329 | $0 |
| % Margin | – | 100% | – | – |
| R&D Expenses | $38,164 | $27,603 | $16,894 | $22,360 |
| G&A Expenses | $0 | $6,320 | $0 | $6,287 |
| SG&A Expenses | $12,472 | $6,320 | $5,497 | $6,287 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $32,154 | $0 | -$91 |
| Operating Expenses | $50,636 | $66,077 | $22,391 | $28,647 |
| Operating Income | -$50,894 | -$16,077 | -$22,720 | -$28,647 |
| % Margin | – | -32.2% | – | – |
| Other Income/Exp. Net | $8,636 | $39,247 | -$1,533 | -$354 |
| Pre-Tax Income | -$42,258 | $23,170 | -$24,253 | -$29,001 |
| Tax Expense | $0 | $450 | $0 | $0 |
| Net Income | -$42,258 | $22,720 | -$24,253 | -$29,001 |
| % Margin | – | 45.4% | – | – |
| EPS | -2.18 | 0.9 | -0.97 | -1.15 |
| % Growth | -342.2% | 192.8% | 15.7% | – |
| EPS Diluted | -2.18 | 0.9 | -0.97 | -1.15 |
| Weighted Avg Shares Out | 19,353 | 25,279 | 25,131 | 25,131 |
| Weighted Avg Shares Out Dil | 19,353 | 25,279 | 25,131 | 25,131 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8,905 | $4,606 | $761 | $77 |
| Interest Expense | $0 | $208 | $388 | $332 |
| Depreciation & Amortization | $258 | $195 | $329 | $325 |
| EBITDA | -$42,000 | $23,573 | -$23,536 | -$28,336 |
| % Margin | – | 47.1% | – | – |